


Q3 2022 *results*

sanofi



• Our exceptional results for the third quarter demonstrate that Sanofi is on the right path. We delivered remarkable sales growth and our commitment to breakthrough science is bearing fruit as we achieved key regulatory milestones for three of our priority medicines. •

Paul Hudson
Chief Executive Officer, Sanofi

Company sales and business EPS*

€12,482m

+9.0% (+19.7%)

Q3 2022
company sales**



€2.88

+17.9% (+32.1%)

Q3 2022
business EPS**

* Earnings per share

** Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.

Sales by global business unit




€4,401m

Specialty Care



€3,495m

General Medicines



€3,315m

Vaccines



€1,271m

Consumer Healthcare

Sales by geography

US

€6,042m

Europe

€2,596m



Rest of
the World

€3,844m

Social Impact

Delivering positive impact
on communities and the environment

Sanofi is advancing towards its Net Zero target by 2050.

Two carbon offsetting programs launched with EcoAct in Kenya:

Restoring 500 hectares
of mangroves

- Removes approx. 390 kt CO₂e
- Improves water quality and biodiversity
- Creates jobs

Distributing 18,250 energy-saving
biomass cookstoves

- Avoids approx. 790 kt CO₂e
- Prevents deforestation
- Improves health and social conditions of local rural families

For further information on Q3 2022 results and definitions of financial indicators, please refer to the press release issued on October 28, 2022 at: www.sanofi.com/en/investors

sanofi



@Sanofi



@Sanofi



@Sanofi



@SanofiaventisTVen